A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

NCT06054555 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

633

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: ABP 206
DRUG: Nivolumab

Sponsor

Amgen